Contemporary mean inundation fraction in the Amazon basin. by Nic Gedney (19762301)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

The contemporary, long-term seasonality in inundation over the whole of the Amazon basin. by Nic Gedney (19762301)

Subjects:

Scatter and line plots of cluster number and mean cluster size as wgs percentage in mixture increases, subset dataset. by August Guang (9975678)

Subjects:

Scatter and line plots of cluster number and mean cluster size as wgs percentage in mixture increases, full dataset. by August Guang (9975678)

Subjects:

Principle Coordinates Analysis (PCoA) projected onto 2 dimensions between pol-wgs mixtures and nFL genome, full dataset by August Guang (9975678)

Subjects:

Principle Coordinates Analysis (PCoA) projected onto 2 dimensions between pol-wgs mixtures and nFL genome, subset dataset by August Guang (9975678)

Subjects:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. by Francesca Catto (21253435)

“…Additionally, there is an increase in plaque size mainly observed in the olfactory, hippocampal, cortical, and striatal areas. (D) Long-term treatment with a high dose of netoglitazone displays a decrease in plaque size, particularly observed in the orbital cortex, olfactory area, hippocampus, thalamus, hypothalamus, midbrain, and hindbrain regions.…”

Box plots showing baseline prevalence and mean egg count at pre-MDA1 in districts that were responders compared to those that were persistent hotspots of decreasing praziquantel ef... by Takafira Mduluza (39754)

Knockdown of ATP2C1 results in a minor decrease of [Ca²⁺] in WPB. by Julian Terglane (12975565)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects: